Rong Yang

Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study

Jean‐Michel Molina, Jaime Andrade‐Villanueva, Juan Echevarría et al. · The Lancet · 2008 · 482 citations

Treatment And Prevention, Antiviral Drug Development, Clinical Trials +9

Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post‐liver transplantation recurrence

Fred Poordad, Eugene R. Schiff, John M. Vierling et al. · Hepatology · 2016 · 456 citations · Full text

Once-Daily Atazanavir/Ritonavir Compared With Twice-Daily Lopinavir/Ritonavir, Each in Combination With Tenofovir and Emtricitabine, for Management of Antiretroviral-Naive HIV-1–Infected Patients: 96-Week Efficacy and Safety Results of the CASTLE Study

Jean‐Michel Molina, Jaime Andrade‐Villanueva, Juan Echevarría et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2010 · 253 citations

Genome-wide association study for vitiligo identifies susceptibility loci at 6q27 and the MHC

Cheng Quan, Yunqing Ren, Leihong Xiang et al. · Nature Genetics · 2010 · 216 citations

Genome-wide Association Study, Disease Susceptibility, Medicine +10

Prevalence and Clinical Significance of HIV Drug Resistance Mutations by Ultra-Deep Sequencing in Antiretroviral-Naïve Subjects in the CASTLE Study

Max Lataillade, Jennifer Chiarella, Rong Yang et al. · PLoS ONE · 2010 · 130 citations · Full text